These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Urine chemical content may be a false measure of environmental exposure. Brent RL Pediatrics; 2013 Sep; 132(3):e747-8. PubMed ID: 23958777 [No Abstract] [Full Text] [Related]
5. Bisphenol A in Hemodialysis Patient: An Open Question. Neri M Blood Purif; 2016; 42(1):75-6. PubMed ID: 27189594 [No Abstract] [Full Text] [Related]
6. Obesity, diabetes and cardiovascular disease: is the fat lady singing? Grant PJ Diab Vasc Dis Res; 2006 May; 3(1):5-6. PubMed ID: 16784174 [No Abstract] [Full Text] [Related]
7. Obesity: Fat from plastics? Linking bisphenol A exposure and obesity. Nadal A Nat Rev Endocrinol; 2013 Jan; 9(1):9-10. PubMed ID: 23147575 [No Abstract] [Full Text] [Related]
8. Bisphenol-A treatment during pregnancy in mice: a new window of susceptibility for the development of diabetes in mothers later in life. Alonso-Magdalena P; García-Arévalo M; Quesada I; Nadal Á Endocrinology; 2015 May; 156(5):1659-70. PubMed ID: 25830705 [TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations. Zarich SW Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752 [TBL] [Abstract][Full Text] [Related]
10. What do cancer, diabetes, and cardiovascular disease have in common? Van Horn L J Am Diet Assoc; 2009 Aug; 109(8):1329. PubMed ID: 19631034 [No Abstract] [Full Text] [Related]
11. Bisphenol A and human chronic diseases: current evidences, possible mechanisms, and future perspectives. Rezg R; El-Fazaa S; Gharbi N; Mornagui B Environ Int; 2014 Mar; 64():83-90. PubMed ID: 24382480 [TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. De Taeye B; Smith LH; Vaughan DE Curr Opin Pharmacol; 2005 Apr; 5(2):149-54. PubMed ID: 15780823 [TBL] [Abstract][Full Text] [Related]
13. The thrifty 'catch-up fat' phenotype: its impact on insulin sensitivity during growth trajectories to obesity and metabolic syndrome. Dulloo AG; Jacquet J; Seydoux J; Montani JP Int J Obes (Lond); 2006 Dec; 30 Suppl 4():S23-35. PubMed ID: 17133232 [TBL] [Abstract][Full Text] [Related]
14. The role of adiponectin in obesity, diabetes, and cardiovascular disease. Kawano J; Arora R J Cardiometab Syndr; 2009; 4(1):44-9. PubMed ID: 19245516 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. McLaughlin T; Abbasi F; Lamendola C; Reaven G Arch Intern Med; 2007 Apr; 167(7):642-8. PubMed ID: 17420421 [TBL] [Abstract][Full Text] [Related]
17. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. Goran MI; Ball GD; Cruz ML J Clin Endocrinol Metab; 2003 Apr; 88(4):1417-27. PubMed ID: 12679416 [TBL] [Abstract][Full Text] [Related]
18. New insights into understanding cardiometabolic risk. Introduction. Fonarow GC; Watson KE Rev Cardiovasc Med; 2007; 8 Suppl 4():S1-2. PubMed ID: 17934389 [No Abstract] [Full Text] [Related]
19. Association of bisphenol A with diabetes and other abnormalities. Wei M JAMA; 2009 Feb; 301(7):720; author reply 721-2. PubMed ID: 19224745 [No Abstract] [Full Text] [Related]
20. The safety of the use of bisphenol A in medical devices. Testai E; ; Hartemann P; Rodríguez-Farre E; Rastogi SC; Bustos J; Gundert-Remy U; Hensten A; Kopperud HM; Olea N; Piersma A; De Jong W; Regul Toxicol Pharmacol; 2016 Aug; 79():106-107. PubMed ID: 26851507 [No Abstract] [Full Text] [Related] [Next] [New Search]